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Chondrogenesis and subsequent osteogenesis of mesenchymal stem cells (MSCs) and angiogenesis at injured sites are crucial for
bone fracture healing. Amygdalin, a cyanogenic glycoside compound derived from bitter apricot kernel, has been reported to
inhibit IL-1β-induced chondrocyte degeneration and to stimulate blood circulation, suggesting a promising role of amygdalin
in fracture healing. In this study, tibial fractures in C57BL/6 mice were treated with amygdalin. Fracture calluses were then
harvested and subjected to radiographic, histological, and biomechanical testing, as well as angiography and gene expression
analyses to evaluate fracture healing. The results showed that amygdalin treatment promoted bone fracture healing. Further
experiments using MSC-specific transforming growth factor- (TGF-) β receptor 2 conditional knockout (KO) mice
(Tgfbr2Gli1-Cre) and C3H10 T1/2 murine mesenchymal progenitor cells showed that this effect was mediated through TGF-
β/Smad signaling. We conclude that amygdalin could be used as an alternative treatment for bone fractures.
1. Introduction
Bone fractures, mainly caused by traumatic incidents and
medical conditions, including osteoporosis, are a growing
global health burden currently affecting millions of people
[1, 2]. Even with treatment, fractures are associated with
great economic burden, loss of independence, and high rates
of morbidity and mortality [3]. In clinical practice, fractures
can be stabilized using various fixation methods, such as
braces and internal, external, and intramedullary fixation
[4–6]. However, fracture nonunion is observed in 5-10% of
patients annually [7]. In addition, bedfast patients receiving
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conservative treatment have higher risks of pressure ulcers,
hypostatic pneumonia, lower extremity venous thromboem-
bolism, and death.
Bone fracture healing is a complicated biological process
that involves specific regenerative patterns and diverse gene
expression changes [8, 9]. Secondary healing is the most
common form of bone healing, which normally includes
endochondral and intramembranous bone healing that can
be separated into three consecutive stages: inflammation,
bone repair, and remodeling [9]. The inflammatory phase is
characterized by the formation of a hematoma and the
immediate release of soluble inflammatory mediators that
induce immune cell infiltration [10].
Mesenchymal stem cells (MSCs) canmigrate to the fracture
site and differentiate into chondrocytes, which form a cartilagi-
nous soft callus. This primary callus is subsequently surrounded
by new bone material produced by osteoblasts in the perichon-
drium and permeated with blood vessels. The cartilaginous
callus then undergoes remodeling to replace the cartilage with
new bone. Thus, the promotion of chondrogenesis/osteogenesis
and angiogenesis can accelerate fracture healing. The origin of
MSCs is not fully understood, but the recruitment, proliferation,
and differentiation of these cells are indispensable for fracture
healing [11]. Successful bone repair and remodeling are also
dependent on an adequate blood supply and revascularization
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Figure 1: Amygdalin accelerated bone fracture healing in mice. (a) The chemical structure of amygdalin. (b) X-ray images and radiographic
union scores showed clear fracture lines at days 4-21 in mice of the control group, but only at days 4-10 in the amygdalin-treated group. Red
arrows point to clear fracture lines. (c). μCT three-dimensional images of fractured tibiae from both groups at days 4, 7, 10, 14, and 21.
Scale bar = 500μm. (d) μCT analysis of BV/TV. Data are presented as mean ± standard deviation (SD). ∗P < 0:05, n = 6.
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Amygdalin (D-mandelonitrile-β-gentiobioside) is derived
from bitter apricot kernel and has been used clinically for the
treatment of asthma, aplastic anemia, tumors, and alloxan-
induced diabetes [13–15]. Amygdalin has also been reported
to inhibit IL-1β-induced chondrocyte degeneration in
endplates and to both improve microcirculation and relieve
blood stasis [16, 17]. Amygdalin has been implicated in the
regulation of transforming growth factor- (TGF-) β/Smad
signaling [18], which has a fundamental regulatory function
for bone homeostasis [19, 20]. Therefore, we hypothesized
that amygdalin can promote bone fracture healing through
TGF-β/Smad signaling.
2. Materials and Methods
2.1. Preparation and Administration of Amygdalin. Amygda-
lin (CAS NO. 29883-15-6, purity ≥ 97:0%, Sigma, St. Louis,
MO, USA) (Figure 1(a)) used in this study was purchased
from the National Institutes for Food and Drug Control of
China and dissolved in sterile normal saline (NS)
(0.05mg/mL). In the amygdalin-treated group, mice were
intraperitoneally injected with 0.5mg/kg of amygdalin daily
from day 1 postoperation. Mice in the control group were
intraperitoneally injected with an equal amount of
phosphate-buffered saline (PBS).
2.2. Experimental Animals. This study was approved by the
Animal Experimentation Ethics Committee of Zhejiang Chi-
nese Medical University. The animal center of the Zhejiang
Chinese Medical University provided C57BL/6 mice (SCXK,
Shanghai, 2012-0002). Gli1-CreER transgenic mice can effi-
ciently target MSCs by injecting tamoxifen (TM) to induce
the formation of Cre (CreERT2) from the endogenous Gli1
locus [21]. The Gli1-CreER transgenic mice were crossed
with Tgfβr2flox/flox mice [22] to specifically knock out the
TGF-β receptor 2 (Tgfbr2) in MSCs. Tamoxifen was admin-
istered (5mg, dissolved in corn oil) once daily for 5 consecu-
tive days by intraperitoneal injection.
A DNA extraction kit (Sigma, USA) was used to deter-
mine mouse genotyping. The sequences of primers used for
genotyping were as follows: Cre, Fw: 5′-ATT GCT GTC
ACT TGG TCG TGGC-3′; Rv: 5′-GAA AAT GCT TCT
GTC CGT TTGC-3′; Tgfbr2 loxP, Fw: 5′-TAA ACA AGG
TCC GGA GCC CA-3′; Rv: 5′-ACT TCT GCA AGA GGT
CCC CT-3′ (wild-type, 420-base-pair PCR product; homo-
zygotic type, 540-base-pair PCR product). Cre-negative
littermates were used as controls.
2.3. Cell Culture. C3H10 T1/2 murine mesenchymal progen-
itor cells (ATCC, Manassas, VA, USA) were cultured in Dul-
becco’s modified Eagle medium (DMEM) (Hyclone, Logan,
Utah, USA) supplemented with 10% fetal bovine serum
(FBS), 100U/mL penicillin and 100mg/mL streptomycin
(Gibco, Grand Island, NY, USA) in a 5% CO2 humidified
incubator at 37°C. After reaching 80% confluence, cells were
collected and divided into the control group, the TGF-β1
group (treated with 10ng/mL recombinant TGF-β1), the
amygdalin group (treated with 10μM amygdalin), the TGF-
β1 plus TGF-β/Smad pathway inhibitor-SB525334 group
(treated with 10 ng/mL recombinant TGF-β1 and 10μM
SB525334), the amygdalin plus SB525334 group (treated with
10μM amygdalin and 10μM SB525334), and the SB525334
group (treated with 10μM SB525334). After 4 hours of treat-
ment, the cells were collected, and changes in the levels of
phosphorylated-Smad2/3 were analyzed. In addition, relative
chondrogenic (Col2a1, Sox9) gene expressions were analyzed
following three days in culture.
2.4. Tibial Fracture Model. Right transverse tibial fractures
were performed and fixed with an intramedullary needle
[23]. Ten-week-old male C57BL/6, Tgfβr2f/f, and
Tgfβr2Gli1Cre mice were anesthetized with ketamine
(60mg/kg) by intraperitoneal injection. After local disinfec-
tion, a 1.0 cm long cut in the anteromedial skin of the tibia
was created. A 26-gauge syringe needle was then inserted into
the bone marrow cavity through the tibial plateau at the
medial of patellar ligament. The needle was then removed,
and the tibia was transected using a No.11 surgical blade.
The 26-gauge syringe needle was reinserted into tibia to sim-
ulate intramedullary fixation. A 5-0 silk suture was selected to
close the incision, and buprenorphine administration (in
drinking water) was used to reduce pain during the first three
days following surgery. Immediately following surgery, X-ray
tests (Carestream, FX Pro, USA) were performed on the right
lower limb in the anterior-posterior and lateral directions to
confirm the correctness of osteotomy and the alignment of
the bone. The mice were then divided into groups for
analysis: C57BL/6 mice treated with amygdalin or PBS, and
Tgfβr2Gli1Cre and Cre-negative controls both treated with
amygdalin.
2.5. X-Ray and μCT Analyses. At days 4, 7, 10, 14, and 21
postsurgery, mice were euthanized, and tibiae were collected
for X-ray and microcomputed tomography (μCT) (Skyscan

















1176; Bruker μCT, Kontich, Belgium) analyses to examine
fracture healing quality. At each time point, harvested speci-
mens were scanned using μCT at 8.73-micron isotropic reso-
lution, with settings of 42 kV and 555μA and 786ms
integration time. Followed by radiographic union scale
(RUST) in the tibial fracture score system, semiquantitative
analyses of the X-ray were performed. Callus bone volume
(BV) and callus mineralized volume fraction (BV/TV) (%)
parameters were then measured.
2.6. Biomechanical Testing. Full-length tibiae were harvested
and removed from their surrounding soft tissues (n = 6 at
days 4, 7, 10, 14, and 21). Both ends of each tibia were then
fixed in bone cement to ensure that the fracture site was
exposed. Specimens were installed on an Endura Tec Test-
Bench TM system (200Nmm torque cell; Bose Corporation,
Minnetonka, MN, USA) to apply torsion at a rate of 1°/s until
failure to determine the modulus of elasticity and maximum
loading of the fracture callus.
2.7. Histology and Histomorphometry. After three days of fix-
ation with 10% normal buffered formalin, the bone samples
were decalcified in 14% ethylenediaminetetraacetic acid
(EDTA) for two weeks. The decalcified bones were dehy-
drated and embedded in paraffin and sectioned (3μm).
Alcian blue/H&E (ABH) staining and tartrate-resistant acid
phosphatase (TRAP) staining were performed. Quantitative
histomorphometry was performed on the ABH- and
TRAP-stained sections using the ImageJ 1.46r software
(Wayne Rasband, National Institute of Health, USA). The
cartilage area per periosteal callus area (%, Cg.Ar/http://Ps
.Cl.Ar) and the mineralized area per periosteal callus area
(%, Md.Ar/http://Ps.Cl.Ar) were measured as described pre-
viously [24]. Immunohistochemistry (IHC) was performed
on sections using high-pressure heating in pH6.0 sodium cit-
rate solution for 2 minutes to achieve antigen retrieval. The
tissues were then incubated with a rabbit anti-mouse anti-
p-Smad2 antibody (Abcam, ab188334, 1 : 200), anti-
pSmad1/5/8 antibody (Millipore, AB3848, 1 : 200), and anti-
CD31 antibody (Arigo, ARG52748, 1 : 100) overnight at
4°C. PBS was incubated on negative group slides. The follow-
ing day, a biotinylated anti-rabbit secondary antibody and an
enzyme conjugate (Histostain-Plus Kit, Invitrogen, USA)
were separately incubated on sections. IHC signals were
developed using DAB chromogen (Histostain-Plus Kit) and
counterstained for nuclei using Tacha’s CAT Hematoxylin.
2.8. Quantitative Real-Time Polymerase Chain Reaction. The
callus was cut with a range of 2mm around the fracture line.
Total RNA was extracted from the callus and three dupli-
cated wells of C3H10 T1/2 cells in the third passage by using
the RNeasy kit (Qiagen, Germany) following the manufac-
turer’s instructions. Then, complementary DNA (cDNA)
was synthesized using a cDNA reverse transcription kit
(Takara, Otsu, Japan). Quantitative real-time polymerase
chain reaction (qRT-PCR) was performed using the SYBR
Premix EX Taq™ kit (Takara) according to the manufac-
turer’s instructions. Primer sequences for Sox9, Col2a1,
Col10a1, Osteocalcin, Runx2, vascular endothelial growth
factor (Vegf), and β-actin are shown in Table 1.
2.9. Western Blot Analysis. Three duplicated wells of
C3H10T1/2 cells at passage 3 were prepared for protein
extraction. Cell lysates were extracted using a modified radio-
immunoprecipitation assay (RIPA) lysis buffer that con-
tained 1mM phenylmethylsulfonyl fluoride (PMSF) and a
protease inhibitor cocktail (Cell Signaling Technology,
USA). Following centrifugation at 12000g for 30 minutes,
the supernatant was collected to detect the total protein con-
centrations using a BCA Protein Assay kit (Thermo Scien-
tific, USA). Protein extracts were boiled for 5 minutes in
loading buffer. Then, 40μg protein was loaded and electro-
phoresed on a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel and transferred to a polyvi-
nylidene difluoride (PVDF) membrane. The membrane was
blocked in a 5% skim milk solution and incubated with pri-
mary antibodies overnight at 4°C. The primary antibodies
were β-actin (Sigma, A1978), Smad2/3 (Cell Signaling Tech-
nology, #8685), and phosphorylated-Smad2/3 (Cell Signaling
Technology, #8828). The membrane was then incubated with
a fluorescent secondary antibody (LI-COR, 926-32212)

















































Figure 2: Biomechanical testing was performed in bone samples harvested at days 10, 14, and 21 after surgery. (a) Maximum loading and (b)
modulus of elasticity were measured in the amygdalin-treated and control groups. Data are presented as mean ± standard deviation (SD).
∗P < 0:05, n = 6.
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Laboratories, Burlingame, VT, USA). The blots were visual-
ized using a LI-COR Odyssey® scanner (LI-COR Biosciences,
USA). The relative density of the p-Smad2/3 bands was
normalized to their corresponding actin bands.
2.10. Wound Scratch Test and Transwell Cell Migration.
C3H10 T1/2 cells were seeded in six-well plates and cultured
with DMEM/F12 supplemented with 5% FBS, 1 × 105 units/L
penicillin, and 100 g/L streptomycin. After reaching 80%-
90% confluence, a scratch of ~0.5mm was made using a
sterile pipette tip and then washed with PBS to clear cellular
debris. After injury, the cells were cultured with low glucose
DMEM/F12 containing 5% (v/v) FBS with 0, 10μM amygda-
lin, 10 ng/mL TGFβ1, 10μM amygdalin plus 10μM
SB525334, 10 ng/mL TGFβ1 plus 10μM SB525334, or
10μM SB525334. The migrations of C3H10 T1/2 cells into
the scratch were photographed using an inverted microscope


























































































Figure 3: Amygdalin accelerated formation of woven bone. (a) Histological sections of the bone fracture with Hematoxylin and Eosin (H&E)
as well as Alcian blue staining. Black arrows represent the cartilage area; yellow arrows highlight the woven bone area. Scale bar = 200 μm. (b)
The cartilage area (blue) of callus tissues (%, Cg.Ar/http://Ps.Cl.Ar) was quantified at days 7, 10, 14, and 21 postfracture in the control and
amygdalin-treated groups. (c) Newly formed woven bone in callus tissues (%, Md.Ar/http://Ps.Cl.Ar) was quantified at days 7, 10, 14, and
21 postfracture in the control and amygdalin-treated groups. (d) Phospho-Smad2 and phospho-Smad1/5/8 protein expressions were
assessed by immunohistochemistry in control and amygdalin-treated groups at days 7 and 10, separately. Blue arrows: p-Smad2 positive
cells. Scale bar = 50 μm. Data are presented as mean ± standard deviation (SD). (e) Tartrate-resistant acid phosphatase (TRAP) staining
and quantification of osteoclast surface per bone surface (Oc. S./BS) of sections from control and amygdalin-treated groups at day 14 after
surgery. Scale bar = 100μm. ∗P < 0:05, n = 6.
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Transwell assays were performed using 8μm-pore Trans-
well polycarbonate membranes (Corning Inc., Corning, New
York, USA). 1:0 × 104 cells were seeded with 200μL
DMEM/F12 containing 2% FBS in the upper chamber, and
in the lower chamber, 500μL DMEM/F12 containing 2%
FBS with 0, 10μM amygdalin, 10 ng/mL TGFβ1, 10μM
amygdalin plus 10μM SB525334, 10 ng/mL TGFβ1 plus
10μM SB525334, or 10μM SB525334. After incubating for
48 h, the migratory cells were fixed with 4% paraformalde-
hyde for 15min and stained with crystal violet. Three
random images were taken in the fields.
2.11. In Vivo Angiography. After injecting a mouse with keta-
mine (60mg/kg), the right atrium was perforated, and 10mL
PBS/heparin sodium was injected through the apex of the left
ventricle. Subsequently, 10mL of 4% paraformaldehyde was
perfused using the same method. Finally, 10mL MICROFIL
was injected with more pressure due to its viscosity and con-
served overnight at 4°C. Muscles around the bone callus were
removed to eliminate the influence of muscle blood vessels.
μCT scanning was first used to locate the callus surrounding
the fracture. After decalcification of the harvested bone sam-
ples for 3 days, the samples were scanned again, using the
same volume of interest (VOI). The analysis area included
400 slices by considering the fracture line as the midline.
The CTAn Software (Skyscan, Version 1.16) was used to
build three-dimensional (3D) models and to measure relative
vessel volume.
2.12. Statistical Analysis. All data were obtained from 6
individual mice in every experiment and 3 duplicated wells
of C3H10 T1/2 cells. Values are showed as the mean. Two-
way ANOVA followed by the Tukey-Kramer posttest (multi-












































































































































Figure 4: Amygdalin upregulated expression of chondrogenesis-, osteogenesis-, and angiogenesis-related genes in the callus. (a–f)
Expressions of Sox9, Col2a1, Col10a1, Runx2, Ocn, and Vegf were measured by quantitative real-time polymerase chain reaction (PCR)
between control and amygdalin groups at days 7, 10, 14, and 21 postfracture. Data are the relative expression versus housekeeping gene β-
actin and are presented as mean ± standard deviation (SD). ∗P < 0:05, n = 6.
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used for statistical analyses. The SPSS 17.0 software was used
to perform the statistical tests. P < 0:05 was considered
significant.
3. Results
3.1. Amygdalin Facilitates Bone Fracture Healing in Mice. To
assess the effects of amygdalin on fracture healing, mice were
treated with PBS or amygdalin (0.5mg/kg/day). X-ray results
showed that treatment with amygdalin promoted earlier for-
mation of bone callus (Figure 1(b)). In the amygdalin group,
a clear callus profile could be observed at day 10, and the
callus became more radiopaque at day 14 postfracture. In
contrast, the callus was not apparent in the control group
until day 14 postfracture.
In addition, 3D reconstructions of μCT images showed
that obvious fracture gaps could be observed in the control
group at days 4, 7, 10, and 14, and newly formed bone had
not fully bridged the gaps until day 21 (Figure 1(c), left). In
contrast, in the amygdalin-treated group, the fracture gap
appeared indistinct at day 14, indicating a higher proportion
of mineralized bone in the callus (Figure 1(c), right). μCT
analysis revealed that the bone volume (%, BV/TV) in the
amygdalin group was significantly increased compared to
the control group at days 10 and 14 (Figure 1(d)), consistent
with the radiographic results.
Furthermore, biomechanical testing showed that the
modulus of elasticity and maximum loading increased signif-
icantly in tibia samples at days 10, 14, and 21 in the
amygdalin-treated group compared to the PBS control group
(P < 0:05). These data demonstrated that bone mechanical
strength has been improved by amygdalin treatment
(Figure 2).
Because radiographic evaluation cannot detect changes in
cartilage and soft tissues, Alcian blue/Hematoxylin/Orange G
(ABH/OG) staining and histomorphometric analysis of the
fractured bone were performed. The cartilage area (%,
Cg.Ar/http://Ps.Cl.Ar) was significantly reduced by day 14
postfracture, and the mineralized bone area was significantly
increased (%, Md.Ar/http://Ps.Cl.Ar) at days 10-21 postfrac-
ture in amygdalin-treated mice compared to the control. At
day 21, the cartilage was no longer detectable in either group
(Figures 3(a)–3(c)). In addition, phospho-Smad2 and phos-
pho-Smad1/5/8 IHC was performed to observe activation
of TGF-β/Smad and BMP2 signaling during fracture healing.
As shown in Figure 3(d), amygdalin treatment could increase
phospho-Smad2 expression at day 7 but have no obvious
effect on phospho- Smad1/5/8 expression at day 10. TRAP
staining was also performed in the fracture callus at day 14.
No significant changes in osteoclast numbers were found
after amygdalin treatment at day 14 (Figure 3(e)).
We also measured the expression of marker genes related
to bone fracture healing. The gene expression of early chon-
drogenesis, such as Sox9 and Col2a1, was similar in
amygdalin-treated and control mice during fracture healing,
except that Sox9 expression was reduced at day 21
(Figures 4(a) and 4(b)). Levels of Col10a1, a marker of late
hypertrophic cartilage, were upregulated at days 10 and 14
in the amygdalin treatment group (Figure 4(c)); this sup-
ported the histologic results of decreased cartilage area at
day 14. Osteogenic marker genes, runt-related transcription


























Figure 5: Amygdalin promoted angiogenesis in the newly formed callus around the fracture. (a) Three-dimensional images and quantification
of angiography around the fractures in control and amygdalin-treated mice 10 days after surgery. Quantification shows the vessel volume.
Scale bar = 1mm. (b) CD31 protein expression was assessed by immunohistochemistry in control and amygdalin-treated groups (day 10).
Blue arrows: CD31-positive cells. Scale bar = 50 μm. Data are presented as mean ± standard deviation (SD). ∗P < 0:05, n = 6.
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at days 10 and 14 in the amygdalin treatment group com-
pared to the control group (Figures 4(d) and 4(e)). In addi-
tion, expression of Vegf at days 10 and 14 was increased in
the amygdalin-treated group compared to the controls, indi-
cating that amygdalin may stimulate angiogenesis during
fracture healing (Figure 4(f)).
Angiographic results demonstrated that amygdalin stimu-
lated angiogenesis and increased the vessel volume in the carti-
laginous bone around the fracture callus (P < 0:05)
(Figure 5(a)). Protein expression of the endothelial cell marker,
CD31, was assessed by IHC at the callus area on day 10. Frac-
ture callus samples from amygdalin-treated mice showed
increased CD31 expression (Figure 5(b)), consistent with
upregulation of the angiogenesis-related marker gene Vegf.
3.2. Amygdalin Accelerates Bone Fracture Healing through
TGF-β/Smad Signaling of MSCs In Vivo. TGF-β/Smad sig-
naling plays fundamental roles in bone homeostasis [25],
and amygdalin has been implicated in the regulation of this
pathway. To determine whether TGF-β/Smad signaling in
MSCs is directly required for amygdalin-induced fracture
healing, tibia fractures were performed on MSC-specific
Tgfβr2 conditional KO (Tgfβr2Gli1Cre) mice and Cre-
negative mice.
To determine the Tgfβr2 knockout efficiency in
Tgfβr2Gli1Cre mice, IHC of p-Smad2 on fracture callus sec-
tions of Cre-negative mice and Tgfbr2Gli1Cre mice at day 10
was performed. The protein expression of p-Smad2 was obvi-
ously reduced in Tgfbr2Gli1Cre mice, indicating inhibition of
TGFβ/Smad pathway signaling (Figure 6(a)). Following frac-
tures, amygdalin was administrated to all mice. X-ray results
showed that fracture lines disappeared at days 14 and 21 in
the Cre-negative group but were still clearly visible until
day 21 in the Tgfβr2Gli1Cre group (Figure 6(b)). Furthermore,
μCT results indicated that amygdalin treatment increased
bone volume and BV/TV around the fracture lines in Cre-
negative mice compared to the Tgfβr2Gli1Cre mice, especially
at days 10 and 14 (Figures 6(c) and 6(d)).
In histological analyses of fracture callus tissues, the
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Figure 6: Amygdalin promoted bone fracture healing in the Cre-negative group compared with the Tgfβr2Gli1Cre group. (a) Phospho-Smad2
protein expression was assessed by immunohistochemistry in the Cre-negative and Tgfβr2Gli1Cre groups (day 7). Scale bar = 50 μm. (b) X-ray
results of fractures in the amygdalin-treated Tgfβr2Gli1Cre group and Cre-negative mice. Red arrows indicate fracture lines. (c, d) μCT analysis
of the bone volume and BV/TV (%) in callus tissues at days 7, 10, 14, and 21 postfracture in amygdalin-treated Tgfβr2Gli1Cre and Cre-negative
mice. Scale bar = 500 μm. Data are presented as mean ± standard deviation (SD). ∗P < 0:05, n = 6.
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(Figure 7(a)). The cartilage area (%, Cg.Ar/http://Ps.Cl.Ar) in
Tgfβr2Gli1Cre mice was significantly increased compared with
controls at day 14 (Figure 7(b)). In addition, Tgfβr2Gli1Cre
mice showed a weaker ability for formation of woven bone
at days 10, 14, and 21 postfracture (Figure 7(c)), indicating
its slower transformation from cartilage into woven bone.
Even though the osteoclast number in Cre-negative mice
was higher than that in Tgfβr2Gli1Cre mice, the difference
was not significant (Figure 7(d)).
3.3. Amygdalin Promotes Migration and Differentiation of
MSCs through TGF-β/Smad Signaling In Vitro. Yu Shi et al.
[21] recently found that Gli1+ osteogenic mesenchymal pro-
genitors mainly facilitate normal bone formation and frac-
ture healing. To determine if amygdalin promotes MSC
migration and differentiation through TGF-β/Smad signal-
ing, we conducted in vitro wound scratch tests and Transwell
cell migration assays using C3H10 T1/2 cells. Both TGF-β1
(10 ng/mL) and amygdalin (10μM) treatment significantly
enhanced the migration of C3H10 T1/2 cells, which could
be effectively inhibited after TGFβ/Smad signaling was
blocked by treating with SB525334 (Figure 8).
Furthermore, TGF-β1 and amygdalin promoted chon-
drogenesis in C3H10 T1/2 cells, as shown by the upregula-
tion of chondrogenic genes, including Sox9, Col2a1, and
Tgfbr2 (Figure 9(a)). However, the effect was obviously inhib-
ited by treatment with SB525334. In addition, phosphory-
lated SMAD2/3, which can regulate chondrogenesis of
MSCs, was analyzed to explore the mechanism of
amygdalin-induced early chondrogenic differentiation of
MSCs. The p-SMAD2/3 protein expression was significantly
























































































Figure 7: (a) Histological images of amygdalin-treated Tgfβr2Gli1Cre and Cre-negative control mice stained with Alcian blue/Hematoxylin
and Eosin (ABH). Black arrows designate chondrocytes; yellow arrows highlight woven bone. Scale bar = 200 μm. (b, c) The cartilage area
of the callus (%, Cg.Ar/http://Ps.Cl.Ar) and newly formed woven bone (%, Md.Ar/http://Ps.Cl.Ar) were quantified at days 7, 10, 14, and
21 in amygdalin-treated Tgfβr2Gli1Cre and Cre-negative control mice. (d) Tartrate-resistant acid phosphatase (TRAP) staining and
quantification of osteoclast surface per bone surface (Oc. S./BS) of sections from amygdalin-treated Tgfβr2Gli1-Cre and Cre-negative mice
(day 14). Scale bar = 100μm. Data are presented as mean ± standard deviation (SD). ∗P < 0:05, n = 6.
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upregulation was inhibited in C3H10T1/2 cells treated with
amygdalin plus SB525334 (Figure 9(b)). These results indi-
cate that amygdalin can promote MSC migration and differ-
entiation through TGF-β/Smad signaling.
4. Discussion
Bone fracture is common clinically and can cause significant
patient morbidity. Several products, such as Dalbergia sissoo,
Peperomia pellucida, and leaves of the Ginkgo biloba tree,
have been investigated for potential effects on fracture repair
[26–28]. The effect and molecular mechanisms of amygdalin
on fracture healing, however, has not been determined. Our
study demonstrated that treatment with amygdalin promotes
fracture healing mainly through TGF-β/Smad signaling in
MSCs.
Initially, two doses (0.5 and 1.0mg/kg/day) of amygdalin
were used to treat fractures in C57BL/6 mice. However, in
consideration of the better effects of treatment with amygda-
lin at 0.5mg/kg/day in preexperiments, we selected this lower
dose for subsequent experiments. The results showed that
amygdalin treatment significantly promoted endochondral
ossification in the fracture callus. Radiographic data demon-
strated that the radiographic union score increased after 10
days in the amygdalin group compared to the control group.
μCT analysis determined that amygdalin treatment signifi-
cantly promoted deposition of osteoid callus, which filled
the fracture gap with a higher proportion of mineralized
bone, accompanied by increased bone volume. This conclu-
sion is consistent with the results of histologic and histomor-
phometric analyses.
Fracture healing is a dynamic process. In mice, indirect
fracture healing (also known as secondary healing) is the
most common form of bone healing, usually consisting of
stages of fibrocartilaginous callus formation, bony callus for-
mation, and bone remodeling. The bone remodeling is initi-
ated in mice from day 14 after amygdalin treatment. It is
attributable to osteoclast-induced bony callus volume reduc-
tion. Radiographic union scores consist of callus formation
and fracture line existence. Although there is no change of
callus formation between groups, we observed fracture line
and increased total radiographic union scores, which are
the other indicators of improved fracture healing, in
amygdalin-treated group. Fracture lines were clear at day
21 in the control group, but blurred in the amygdalin group
at the same time point, indicating a better connection of cor-
tical bone. Thus, biomechanical properties were improved
with amygdalin treatment at day 21. Amygdalin treatment
reduced the cartilage area and accelerated woven bone for-
mation. However, amygdalin treatment did not increase the
cartilaginous composition in early fracture callus compared
to the control group. Because mineralization of the cartilagi-
nous callus and formation of woven bone were increased by
amygdalin treatment, the cartilage area of callus tissues began
to decrease after day 14 compared to the control group. The
transition from chondrogenesis to osteogenesis was associ-
ated with decreased gene expression of Sox9, a marker of
chondrogenic differentiation [29], and increased expression
of osteogenic markers (Runx2 and osteocalcin) after amygda-
lin treatment. Because of further mineralization, angiogene-
sis and endochondral bone formation can be regulated by
the later cartilage hypertrophic marker Col10a1 [29–31].
Similarly, Col10a1 expression was also upregulated in the
amygdalin group at days 10 and 14. In addition to morpho-
logical changes, the mechanical properties of the bone could












Figure 8: Amygdalin promoted C3H10 T1/2 cell migration through transforming growth factor- (TGF-) β/Smad signaling. Red
scale bar = 250μm; black scale bar = 250 μm.
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At the fracture site, angiogenesis and blood supply also
has a direct influence on the fracture healing process. Abun-
dant vascular distribution provides cells, growth factors, and
some other constituents necessary for normal fracture heal-
ing [33, 34]. We performed angiography to examine how
amygdalin impacts angiogenesis and found that it increased
the volume of newly formed vessels in the cartilaginous bone.
In our study, amygdalin significantly increased Vegf expres-
sion and CD31 protein expression in callus tissue; these find-
ings were consistent with the results of increased
angiogenesis. Previous reports revealed that angiogenesis
can be induced by activation of TGF-β signaling [35, 36]
and attenuated after inhibition of ALK5/Smad2/3 [37]. Col-
lectively, amygdalin could promote angiogenesis during frac-
ture healing, mainly dependent on the normal function of
TGF-β/Smad signaling. In our study, amygdalin treatment
could enhance phosphorylation of Smad2 at day 7 in vivo,
indicating that amygdalin can upregulate TGF-β/Smad sig-
naling during the fracture healing process.
During bone fracture healing, MSCs are recruited and
differentiate into chondrocytes that generate cartilage extra-
cellular matrix, which then mineralizes. Eventually, osteo-
blasts penetrate and promote osteogenesis [8, 38]. The
fracture healing process is required for multiple cell types to
repair bone structure [39]. Using lineage-tracing techniques
in vivo, some experiments have shown that perinatal Sox9+,
Col2+, or Agc1+ cells can produce osteoblasts and MSCs in
mice [39]. Recently, however, a new type of cell, Gli1+ cells,
were found to give rise to osteoblasts and chondrocytes in
the process of bone fracture healing and to promote normal
bone formation [21]. Gli1+ cells have been proposed to be
MSCs in many bone-related studies [40, 41]. To determine
whether amygdalin promotes chondrogenic and osteogenic
differentiation of Gli1+ MSCs through TGF-β/Smad signal-
ing, we tracked the fracture healing of Cre-negative and
Tgfβr2Gli1-Cre mice treated with amygdalin. The MSC-
specific loss of Tgfβr2 resulted in delayed maturation and
mineralization of the cartilaginous callus. Remarkably, X-
ray and μCT results showed delayed fracture healing in
Tgfβr2Gli1-Cremice, providing strong evidence that the stimu-
lation of fracture healing by amygdalin depends on TGF-
β/Smad signaling. Consistent with the in vivo results, both
TGF-β1 and amygdalin-activated TGF-β/Smad signaling in
MSCs promoted the migration of MSCs and chondrogenesis
in vitro. Importantly, TGF-β/Smad inhibition by a TGF-β1













































































Figure 9: Amygdalin promoted C3H10 T1/2 cell chondrogenic gene expression through transforming growth factor- (TGF-) β/Smad
signaling. (a) With control (Ctrl: phosphate-buffered saline), TGF-β1, amygdalin, and/or SB525334 treatment in C3H10 T1/2 cells, gene
expressions of Tgfβr2, Col2a1, and Sox9 were measured using qRT-PCR analysis. (b) Western blot analyses for phosphorylated SMAD2/3
were conducted on protein lysates from C3H10 T1/2 cells.
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responses induced by TGF-β1 or amygdalin treatment in
MSCs, confirming that amygdalin promotes facture healing
in a TGF-β/Smad signaling-dependent mechanism.
In conclusion, this study demonstrated that amygdalin
could promote the migration and differentiation of MSCs
to accelerate the fracture healing process by regulating
TGF-β/Smad signaling. These results support the use of
amygdalin-based therapy for fracture healing.
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